Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Chest ; 155(4): e97-e100, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30955587

RESUMO

CASE PRESENTATION: A 73-year-old man presented to the ED of an outside hospital with asymptomatic chest wall swelling 10 h after discharge from our hospital. Four days earlier, he had presented to our hospital with increased dyspnea, cough, and sputum production. His history was notable for severe COPD with bullous emphysema. Chest imaging demonstrated bilateral opacities and a collection of gas and liquid in the major fissure of the left lung. A catheter was placed into the collection of gas and liquid under imaging guidance. After 4 days, the catheter was removed without event and the patient was discharged from the hospital with an extended course of antibiotics. Imaging performed in the ED revealed gas in the tissues of the chest wall and no evidence of a pneumothorax. He was transported back to our hospital by helicopter.


Assuntos
Fístula Brônquica/complicações , Catéteres/efeitos adversos , Fístula Cutânea/complicações , Descompressão Cirúrgica/instrumentação , Remoção de Dispositivo/efeitos adversos , Enfisema Subcutâneo/etiologia , Idoso , Fístula Brônquica/diagnóstico , Fístula Brônquica/cirurgia , Fístula Cutânea/diagnóstico , Fístula Cutânea/cirurgia , Humanos , Masculino , Enfisema Subcutâneo/diagnóstico , Enfisema Subcutâneo/cirurgia , Tomografia Computadorizada por Raios X
4.
Vaccine ; 21(17-18): 2133-44, 2003 May 16.
Artigo em Inglês | MEDLINE | ID: mdl-12706704

RESUMO

We assessed whether trivalent live, cold-adapted influenza virus (CAIV-T) vaccine provides added protection when co-administered with trivalent inactivated influenza virus vaccine (TVV) in patients with chronic obstructive pulmonary disease (COPD). Subjects (N=2215) were randomly assigned to receive either TVV intramuscularly (IM) and CAIV-T intranasally (TC), or TVV and placebo (TP). The vaccines were well-tolerated. Efficacy of TC compared to TP was not statistically significant and was 0.16 for any influenza virus strain (95% confidence limit (CL): -0.22, 0.43), 0.26 for A (H3N2) virus (95% CL: -0.17, 0.53), and -0.05 for type B virus (95% CL: -1.13, 0.48). However, there was a possible advantage for TC over TP in reducing respiratory consequences of an influenza season measured by pulmonary function and symptoms at end of study.


Assuntos
Vacinas contra Influenza/uso terapêutico , Influenza Humana/imunologia , Doença Pulmonar Obstrutiva Crônica/imunologia , Vacinas de Produtos Inativados/uso terapêutico , Administração Intranasal , Idoso , Surtos de Doenças , Humanos , Vacinas contra Influenza/administração & dosagem , Vacinas contra Influenza/imunologia , Influenza Humana/epidemiologia , Injeções Intramusculares , Pessoa de Meia-Idade , Placebos , Doença Pulmonar Obstrutiva Crônica/complicações , Reprodutibilidade dos Testes , Estados Unidos/epidemiologia , Vacinas de Produtos Inativados/administração & dosagem , Vacinas de Produtos Inativados/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA